Hawaiian AG sues Bristol-Myers, Sanofi over Plavix efficacy; Gilead and New York strike an HIV-drug deal;

@FiercePharma: Pay-for-delay: Is cash the only antitrust test that matters in patent settlements? Story | Follow @FiercePharma

@TracyStaton: Should gastro specialist Salix snap up Furiex and its IBS drug candidate? More | Follow @TracyStaton

@EricPFierce: Even an OTC drugmaker can have research published in New England Journal of Medicine. News | Follow @EricPFierce

@CarlyHFierce: Valeant's CEO, a crackerjack cost-cutter, seeks more 'fat' companies to buy. Piece | Follow @CarlyHFierce

> Hawaii's attorney general sued Bristol-Myers Squibb ($BMY) and Sanofi ($SNY), claiming that the drugmakers dragged their feet on pointing out genetic differences that could make their Plavix bloodthinner less effective. Report

> The FDA Wednesday approved Paladin's Impavido to treat a tropical disease transmitted to humans via parasite through fly bites. Report

> Novartis ($NVS) is launching a Lucentis pre-filled syringe in Europe, which it says will reduce the risk of adverse events from non-sterile conditions. Release

> New York has inked a deal with Gilead Sciences ($GILD) to cut the price of HIV-treating drugs, part of the state's plan to cut down its infected population. More

> AstraZeneca ($AZN) will propose international business vet Ann Cairns for election as non-executive director at the company's annual meeting in April. Release

> Mallinckrodt ($MNK) has completed its $1.21 purchase of Cadence Pharmaceuticals ($CADX). Report

> Novartis Animal Health UK is partnering up with Procter & Gamble's ($PG) pet care business. Story

Medical Device News

@FierceMedDev: Corning leads NinePoint's new $34M Series B--a big round for the next-gen imaging tech developer. More | Follow @FierceMedDev

@MarkHFierce: This is the kind of pacer I'd like to try. Wild stuff. Feature via PopSci | Follow @MarkHFierce

@MichaelGFierce: Drug delivery in space? NASA contributes to the field with microcapsules developed by ISS Research. More via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Congress wants more answers from the FDA about its regulation of mobile medical apps. Story | Follow @EmilyWFierce

> St. Jude Medical nails CE mark for 'burst' neurostim treatment of chronic pain. More

> Bacterin 2013 revenues improve slightly; net losses rise significantly. Story

Biotech News

@FierceBiotech: Biotechs bag $170M in IPO cash as a booming quarter winds down. Article | Follow @FierceBiotech

@JohnCFierce: Sanofi launches a vaccine R&D program with blockbuster Prevnar 13 in its sights. News | Follow @JohnCFierce

@DamianFierce: Liver risks put another Geron trial on ice, but the damage has largely been done already. More | Follow @DamianFierce

@EmilyMFierce: Survey: 1 in 5 Americans think doctors know vaccines cause autism. Story via FierceVaccines | Follow @EmilyMFierce

> GlaxoSmithKline's cancer vaccine MAGE-A3 suffers its second PhIII flop. More

> Sanofi launches a vaccine R&D program with blockbuster Prevnar 13 in its sights. Coverage

Pharma Manufacturing News

> Novartis CEO predicts generic industry fallout as quality takes center stage. Story

> FDA jumps compounder for making unapproved domperidone. News

> FDA cuts U.S. plant inspections while boosting them overseas. Story

> Indian regulator finds number of substandard drugs on the rise. Article

> Parexel opens Singapore distribution facility. Story

> OTC maker has discovery published in New England Journal of Medicine. Brief

Vaccines News

> Novartis to submit Bexsero to FDA in Q2. News

> 1 in 5 Americans think doctors know vaccines cause autism. Survey

> Amgen posts positive PhIII data as judgment day for cancer vaccine bet nears. News

> Failure of sexual health clinics to offer HPV vaccine leaves high-risk groups vulnerable. Story

> Circassia begins trading in London following successful IPO. News

> Sanofi inks a Korean alliance to develop a pneumococcal vaccine. Brief

And Finally... New Zealand's AFT Pharmaceuticals says some widely used OTC cold and flu meds may be exposing patients to unexpectedly high levels of nasal decongestant phenylephrine. More (sub. req.)

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.